3 Cancer Treatment Stocks to Buy Right Now
Cancer treatment has undergone a revolution in recent years, creating opportunities for companies pioneering new approaches and their investors. In the last five years, since around the time the first immuno-oncology drugs hit the market, 61 cancer drugs have been launched to treat 23 different kinds of cancers. Last year, worldwide sales of oncology drugs amounted to about $124 billion, more than twice that of any other therapy area, and are growing at a double-digit rate.
Investors wanting to profit from the trend should consider buying several stocks in the space to spread out the risk. There are over 700 cancer drugs in late-stage development, a 60% increase over the number a decade ago, and many of them will fail in clinical trials. But choosing several stocks of companies that have already established a history of success is one way to build a portfolio to take advantage of one of the most innovative and lucrative markets in healthcare.
Three such stocks, spanning the range of market capitalization from pharmaceutical giant to under-the-radar mid-cap, are Merck (NYSE: MRK), Seattle Genetics (NASDAQ: SGEN), and NeoGenomics (NASDAQ: NEO).
Source Fool.com
